Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History MIRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics MIRM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Mirum Pharmaceuticals Inc

MIRM
Current price
52.80 USD +0.68 USD (+1.30%)
Last closed 51.98 USD
ISIN US6047491013
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 625 834 240 USD
Yield for 12 month +37.61 %
1Y
3Y
5Y
10Y
15Y
MIRM
21.11.2021 - 28.11.2021

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. Address: 950 Tower Lane, Foster City, CA, United States, 94404

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

68.60 USD

P/E Ratio

Dividend Yield

Financials MIRM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures MIRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+336 888 000 USD

Last Year

+186 374 000 USD

Current Quarter

+111 585 000 USD

Last Quarter

+99 414 000 USD

Current Year

+255 245 000 USD

Last Year

+139 335 000 USD

Current Quarter

+88 567 000 USD

Last Quarter

+76 634 000 USD
EBITDA -52 304 000 USD
Operating Margin TTM -13.61 %
Price to Earnings
Return On Assets TTM -7.11 %
PEG Ratio
Return On Equity TTM -33.06 %
Wall Street Target Price 68.60 USD
Revenue TTM 379 251 008 USD
Book Value 4.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 61.20 %
Dividend Yield
Gross Profit TTM 292 420 000 USD
Earnings per share -1.61 USD
Diluted Eps TTM -1.61 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -20.39 %

Stock Valuation MIRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 39.68
Enterprise Value Revenue 7.09
Price Sales TTM 6.92
Enterprise Value EBITDA -8.85
Price Book MRQ 11.35

Technical Indicators MIRM

For 52 Weeks

36.20 USD 54.23 USD
50 Day MA 46.89 USD
Shares Short Prior Month 6 218 308
200 Day MA 44.41 USD
Short Ratio 16.87
Shares Short 6 512 657
Short Percent 12.55 %